Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

  • M Gejl
  • H M Søndergaard
  • Chalotte Willemann Stecher
  • Bo Martin Bibby
  • N Møller
  • H E Bøtker
  • S B Hansen
  • Gjedde, Albert
  • Jørgen Rungby
  • B Brock
Glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists provide beneficial cardiovascular effects by protecting against ischemia and reperfusion injury. Type 2 diabetes mellitus patients have reduced glycolysis in the heart.
Original languageEnglish
JournalThe Journal of clinical endocrinology and metabolism
Issue number7
Pages (from-to)E1165-9
Number of pages5
Publication statusPublished - Jul 2012

    Research areas

  • Biological Transport, Coronary Circulation, Cross-Over Studies, Diabetes Mellitus, Type 2, Double-Blind Method, Glucose, Heart, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Middle Aged, Myocardium, Peptides, Placebos, Positron-Emission Tomography, Regional Blood Flow, Up-Regulation, Venoms

ID: 47756542